The Pet Economy’s Perfect Storm

Chewy’s stock price has taken a beating in recent months, sparking debate among investors over whether the company’s growth is slowing or if its Q2 fiscal 2026 results are an overreaction. Morgan Stanley’s latest note on Chewy’s performance highlights a mixed picture: net sales of $3.33 billion, a 7.3% year-over-year increase, but organic growth of only 5.7%, down from 6.9% in Q1.

The current economic climate is likely to blame for this deceleration. As household budgets tighten, pet owners are being forced to make tough choices about how much to spend on their pets. Morgan Stanley’s coined term “treat-cession” accurately describes the impact of these budget constraints on Chewy’s stock price, which has fallen 36.22% year-to-date and 39.96% over the past year.

Morgan Stanley is not entirely bearish on Chewy, however. The firm argues that the sell-off was an overreaction, pointing out that underlying fundamentals were in line with expectations. Nevertheless, Chewy’s growth is slowing, and the company will need to deliver more convincing evidence of its ability to accelerate revenue and expand margins if it wants to win back investors.

One potential catalyst for Chewy’s future growth lies in its expanding healthcare business. By acquiring Modern Animal and SmartPak, Chewy has tapped into a higher-margin segment of the market with stickier customer relationships than commodity pet food. This acquisition-driven growth will be crucial in driving top-line acceleration, especially if Chewy+ membership program takes off.

Chewy’s redesigned membership program is being closely watched by investors, who are eager to see whether it can provide a much-needed boost to revenue and margins. Morgan Stanley estimates that Chewy will target incremental margins of 15% to 18% in fiscal 2027, which would translate to roughly 50 to 70 basis points of EBITDA margin expansion at a firm’s estimated 6.4% revenue growth.

While the bull case for Chewy is intriguing, it remains to be seen whether the company can deliver on its ambitious goals. The bear case, however, is more ominous, with estimates calling for only 4% revenue growth and continued competitive pressure. At around $21, Chewy trades at an estimated 8.5x fiscal 2027 EBITDA, which seems priced for underperformance rather than recovery.

The fate of Chewy’s stock price will depend on its ability to deliver organic growth estimates that start moving higher. The company’s provision of this catalyst in the second half of 2026 could determine whether it can escape the “treat-cession” and regain momentum.

The larger question is what this means for the broader pet industry. With household budgets getting tighter, will consumers continue to prioritize their pets or cut back on discretionary spending? The answer may lie in how companies like Chewy adapt to changing consumer behavior and respond to shifting market conditions. As the industry navigates these uncertain waters, only those that can deliver innovative solutions, robust growth, and solid execution will emerge unscathed.

The Chewy story serves as a microcosm for the broader trends shaping the pet industry today. As we continue to navigate the “treat-cession” and its implications for consumer spending, it’s worth remembering that this is not just about one company or stock – but about an entire ecosystem of businesses reliant on pet owners’ discretionary income. Will Chewy find a way to weather the storm, or will other companies fill the void? The answer may depend on how well these players can adapt to the changing landscape and deliver compelling value propositions for pet owners in uncertain times.

In the end, it’s not just about Chewy’s stock price – but about what this means for the future of the pet industry as a whole. Will consumers continue to prioritize their pets’ health and happiness, or will they cut back on discretionary spending? The answer may lie in how companies like Chewy navigate these uncertain waters and deliver innovative solutions that resonate with pet owners.